SAI Life Sciences Ltd. (IN:SAILIFE)
:SAILIFE
Want to see IN:SAILIFE full AI Analyst Report?
Top Page
SAI Life Sciences Ltd.
(SAILIFE)
Select Model
Select Model
Rating:71Outperform
Price Target:
₹1,204.00
▲(19.18% Upside)
Action:N/A
Date:05/16/26
The score is driven primarily by strong financial performance (rapid growth, expanding margins, improving ROE, and low leverage), tempered by weak cash conversion due to negative free cash flow. Technicals are supportive with a clear uptrend, while the overall rating is capped by a high P/E and no stated dividend yield.
Positive Factors
Revenue & Margin Momentum
Very strong top-line growth and expanding operating profitability indicate the business is scaling with operational leverage. Sustained double-digit net and high-20s EBITDA margins point to durable profit economics as projects move from discovery to higher-value development and manufacturing.
Negative Factors
Persistent Negative Free Cash Flow
Despite strong accounting profits, the company has produced negative free cash flow in consecutive years. Persistent FCF deficits can force external financing, constrain organic funding for capacity or R&D, and increase vulnerability if revenue growth or margins decelerate.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue & Margin Momentum
Very strong top-line growth and expanding operating profitability indicate the business is scaling with operational leverage. Sustained double-digit net and high-20s EBITDA margins point to durable profit economics as projects move from discovery to higher-value development and manufacturing.
Read all positive factors
SAI Life Sciences Ltd. (SAILIFE) vs. iShares MSCI India ETF (INDA)
Market Cap
₹236.68B
Dividend YieldN/A
Average Volume (3M)11.95K
Price to Earnings (P/E)58.4
Beta (1Y)1.11
Revenue GrowthN/A
EPS GrowthN/A
CountryIN
Employees3,401
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)4.01
Shares Outstanding212,023,150
10 Day Avg. Volume10,862
30 Day Avg. Volume11,945
Financial Highlights & Ratios
PEG Ratio0.66
Price to Book (P/B)8.20
Price to Sales (P/S)9.29
P/FCF Ratio-282.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,270.00Price Target Upside25.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)19.54
Revenue Forecast (FY)₹26.60B
SAI Life Sciences Ltd. Business Overview & Revenue Model
Company Description
Sai Life Sciences Limited operates as a contract research, development, and manufacturing organization (CRDMO) in India and internationally. It provides medicinal chemistry, pharmacokinetics, manufacturing, and contract development services. The c...
How the Company Makes Money
SAI Life Sciences makes money by providing fee-based outsourced R&D and manufacturing services to pharmaceutical and biotechnology companies.
Key revenue streams typically include:
- Contract research services: Revenue earned for discovery-stage ...
SAI Life Sciences Ltd. Financial Statement Overview
Summary
Income Statement
86
Very Positive
Balance Sheet
84
Very Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2025 |
|---|---|---|---|
Income Statement | |||
| Total Revenue | 10.83B | 21.92B | 16.96B |
| Gross Profit | 3.95B | 7.72B | 6.19B |
| EBITDA | 3.28B | 6.31B | 4.42B |
| Net Income | 1.72B | 3.49B | 1.70B |
Balance Sheet | |||
| Total Assets | 33.32B | 36.26B | 31.60B |
| Cash, Cash Equivalents and Short-Term Investments | 3.06B | 1.58B | 3.72B |
| Total Debt | 5.64B | 2.88B | 3.52B |
| Total Liabilities | 10.62B | 11.42B | 10.32B |
| Stockholders Equity | 22.70B | 24.84B | 21.28B |
Cash Flow | |||
| Free Cash Flow | -1.98B | -721.30M | -918.36M |
| Operating Cash Flow | 3.06B | 5.21B | 2.77B |
| Investing Cash Flow | -4.40B | -4.18B | -5.53B |
| Financing Cash Flow | 3.08B | -1.13B | 3.54B |
SAI Life Sciences Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ₹236.68B | 58.36 | ― | ― | ― | ― | |
71 Outperform | ₹33.01B | 18.59 | ― | 0.96% | 9.30% | 14.06% | |
70 Outperform | ₹37.24B | 29.96 | ― | 0.13% | 14.96% | 27.42% | |
64 Neutral | ₹7.96B | 19.44 | ― | 1.96% | -3.66% | -65.22% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | ₹19.87B | -14.78 | ― | 0.08% | 10.73% | -31.79% | |
46 Neutral | ₹36.40B | -40.91 | ― | 0.06% | 92.70% | -28.06% |
* Healthcare Sector Average
IN:SAILIFE
SAI Life Sciences Ltd.
1,141.20
400.85
54.14%
IN:INDOCO
Indoco Remedies Limited
211.30
-49.16
-18.87%
IN:INDRAMEDCO
Indraprastha Medical Corporation Limited
360.15
-55.37
-13.33%
IN:KOPRAN
Kopran Limited
167.20
-21.23
-11.27%
IN:SMSPHARMA
SMS Pharmaceuticals Limited
423.85
160.91
61.20%
IN:ZOTA
Zota Health Care Ltd.
1,202.60
202.99
20.31%
SAI Life Sciences Ltd. Corporate Events
Sai Life Sciences Allots 244,281 Shares Under ESOP and Management Plans
Apr 23, 2026
Sai Life Sciences has allotted 244,281 fully paid-up equity shares with a face value of Re 1 each under its Employees Stock Option Plan 2008 and Management ESOP Plan 2018, following board approval on 23 April 2026. The issuance, executed at exerci...
Sai Life Sciences appoints new global PR&D head as senior management leader
Mar 30, 2026
Sai Life Sciences has announced a leadership change in its global process research and development function, appointing Dr. John Pavey as Senior Management Personnel and Head – Global PRD effective 1 April 2026. He succeeds Dr. Dean David Ed...
Sai Life Sciences Closes Trading Window Ahead of FY 2026 Results
Mar 30, 2026
Sai Life Sciences Ltd. has announced a closure of its trading window for designated persons and their immediate relatives starting April 1, 2026, in line with SEBI’s Prohibition of Insider Trading Regulations and the company’s internal...
Sai Life Sciences allots 129,007 equity shares under ESOP schemes
Feb 23, 2026
Sai Life Sciences Limited has allotted a total of 129,007 fully paid-up equity shares of Re 1 each following the exercise of options under its Employees Stock Option Plan 2008 and Management ESOP Plan 2018, as approved by the board on 22 February ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.